Golden cross on moving average.
Average analysts price target $1.17 | Buy rating
IntelGenx Technologies Corp. is a oral drug delivery company, which focuses on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm technology platform. Its products include rizaport, tadalafil, loxapine, and montelukast. The company also offers a comprehensive portfolio of pharmaceutical services, such as pharmaceutical research & development, clinical monitoring, regulatory support, tech transfer & manufacturing scale-up and commercial manufacturing. IntelGenx Technologies was founded on July 27, 1999 and is headquartered in Ville Saint-Laurent, Canada.